Normal human pluripotential and committed hematopoietic progenitors do not express the p24 antigens detected by monoclonal antibody BA-2: Implications for immunotherapy of lymphocytic leukemia

R. C. Ash, J. Jansen, J. H. Kersey, T. W. LeBien, E. D. Zanjani

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Analysis of surface antigenic determinants of hematopoietic progenitor cells has relevance both to basic biologic study of cell differentiation and to potential clinical application in the diagnosis and treatment of hematologic neoplasia. The production and characterization of monoclonal antibody BA-2 by immunization with a pre-B-ALL cell line has been reported previously. In this study we utilized complement-dependent cytotoxicity and rosette-separation with antibody indirectly coupled to ox RBC to determine if the antigen (p24) recognized by the antibody BA-2 is represented on human pluripotential (CFU-GEMM) or committed hematopoietic progenitors (CFU-GM, BFU-E, CFU-E). BA-2 showed no reactivity with normal hematopoietic progenitors by either method. In contrast, BA-2 exhibited potent complement-mediated cytotoxicity for selected ALL-derived cell lines. These results show that normal human hematopoietic progenitors do not express antigenic sites represented on ALL cells that are recognized by BA-2 and suggest that this monoclonal antibody may serve as a potent and specific agent for treatment of lymphocytic marrow conditioning for autologous bone marrow transplantion.

Original languageEnglish (US)
Pages (from-to)1310-1316
Number of pages7
JournalBlood
Volume60
Issue number6
StatePublished - Dec 1 1982

Fingerprint

Lymphoid Leukemia
Immunotherapy
Monoclonal Antibodies
Antigens
Cytotoxicity
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow
Cells
Immunization
Myeloid Progenitor Cells
Cell Line
Granulocyte-Macrophage Progenitor Cells
Erythroid Precursor Cells
B-Lymphoid Precursor Cells
Antibodies
Hematopoietic Stem Cells
Epitopes
Cell Differentiation
Bone
N-methyl-valyl-amiclenomycin

Cite this

Normal human pluripotential and committed hematopoietic progenitors do not express the p24 antigens detected by monoclonal antibody BA-2 : Implications for immunotherapy of lymphocytic leukemia. / Ash, R. C.; Jansen, J.; Kersey, J. H.; LeBien, T. W.; Zanjani, E. D.

In: Blood, Vol. 60, No. 6, 01.12.1982, p. 1310-1316.

Research output: Contribution to journalArticle

@article{d33ee877a78b4c7687e184bed5fefac4,
title = "Normal human pluripotential and committed hematopoietic progenitors do not express the p24 antigens detected by monoclonal antibody BA-2: Implications for immunotherapy of lymphocytic leukemia",
abstract = "Analysis of surface antigenic determinants of hematopoietic progenitor cells has relevance both to basic biologic study of cell differentiation and to potential clinical application in the diagnosis and treatment of hematologic neoplasia. The production and characterization of monoclonal antibody BA-2 by immunization with a pre-B-ALL cell line has been reported previously. In this study we utilized complement-dependent cytotoxicity and rosette-separation with antibody indirectly coupled to ox RBC to determine if the antigen (p24) recognized by the antibody BA-2 is represented on human pluripotential (CFU-GEMM) or committed hematopoietic progenitors (CFU-GM, BFU-E, CFU-E). BA-2 showed no reactivity with normal hematopoietic progenitors by either method. In contrast, BA-2 exhibited potent complement-mediated cytotoxicity for selected ALL-derived cell lines. These results show that normal human hematopoietic progenitors do not express antigenic sites represented on ALL cells that are recognized by BA-2 and suggest that this monoclonal antibody may serve as a potent and specific agent for treatment of lymphocytic marrow conditioning for autologous bone marrow transplantion.",
author = "Ash, {R. C.} and J. Jansen and Kersey, {J. H.} and LeBien, {T. W.} and Zanjani, {E. D.}",
year = "1982",
month = "12",
day = "1",
language = "English (US)",
volume = "60",
pages = "1310--1316",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Normal human pluripotential and committed hematopoietic progenitors do not express the p24 antigens detected by monoclonal antibody BA-2

T2 - Implications for immunotherapy of lymphocytic leukemia

AU - Ash, R. C.

AU - Jansen, J.

AU - Kersey, J. H.

AU - LeBien, T. W.

AU - Zanjani, E. D.

PY - 1982/12/1

Y1 - 1982/12/1

N2 - Analysis of surface antigenic determinants of hematopoietic progenitor cells has relevance both to basic biologic study of cell differentiation and to potential clinical application in the diagnosis and treatment of hematologic neoplasia. The production and characterization of monoclonal antibody BA-2 by immunization with a pre-B-ALL cell line has been reported previously. In this study we utilized complement-dependent cytotoxicity and rosette-separation with antibody indirectly coupled to ox RBC to determine if the antigen (p24) recognized by the antibody BA-2 is represented on human pluripotential (CFU-GEMM) or committed hematopoietic progenitors (CFU-GM, BFU-E, CFU-E). BA-2 showed no reactivity with normal hematopoietic progenitors by either method. In contrast, BA-2 exhibited potent complement-mediated cytotoxicity for selected ALL-derived cell lines. These results show that normal human hematopoietic progenitors do not express antigenic sites represented on ALL cells that are recognized by BA-2 and suggest that this monoclonal antibody may serve as a potent and specific agent for treatment of lymphocytic marrow conditioning for autologous bone marrow transplantion.

AB - Analysis of surface antigenic determinants of hematopoietic progenitor cells has relevance both to basic biologic study of cell differentiation and to potential clinical application in the diagnosis and treatment of hematologic neoplasia. The production and characterization of monoclonal antibody BA-2 by immunization with a pre-B-ALL cell line has been reported previously. In this study we utilized complement-dependent cytotoxicity and rosette-separation with antibody indirectly coupled to ox RBC to determine if the antigen (p24) recognized by the antibody BA-2 is represented on human pluripotential (CFU-GEMM) or committed hematopoietic progenitors (CFU-GM, BFU-E, CFU-E). BA-2 showed no reactivity with normal hematopoietic progenitors by either method. In contrast, BA-2 exhibited potent complement-mediated cytotoxicity for selected ALL-derived cell lines. These results show that normal human hematopoietic progenitors do not express antigenic sites represented on ALL cells that are recognized by BA-2 and suggest that this monoclonal antibody may serve as a potent and specific agent for treatment of lymphocytic marrow conditioning for autologous bone marrow transplantion.

UR - http://www.scopus.com/inward/record.url?scp=0020396217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020396217&partnerID=8YFLogxK

M3 - Article

C2 - 7139121

AN - SCOPUS:0020396217

VL - 60

SP - 1310

EP - 1316

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -